Research Article

CD200R1 regulates eosinophilia during pulmonary fungal infection in mice

Samira Salek-Ardakani1,2, Thomas Bell1, Christopher P Jagger2, Robert J Snelgrove∗1 and Tracy Hussell∗2

1 National Heart and Lung Institute, Department of Inflammation, Development & Repair, Imperial College London, UK
2 Manchester Collaborative Centre for Inflammation Research (MCCIR), Manchester, UK

CD200 receptor 1 (CD200R1) signalling limits myeloid cell responses and reduces autoimmunity, alloimmunity and viral-mediated immunopathology, but has never been examined in the context of eosinophilic inflammation. Susceptibility to lung fungal infection is associated with T-helper 2 (Th2) cytokine dominated responses and strong eosinophilic pathology. Blockade of CD200R1 enhances type I cytokine responses in many infectious and non-infectious settings and so may promote a more protective response to fungal infection. By contrast, we demonstrate that, rather than promoting type I cytokine responses, CD200R1 blockade enhanced eosinophilia in a mouse model of Cryptococcus neoformans infection, whereas CD200R1 agonism reduced lung eosinophilia – with neither strategy completely altering fungal burden. Thus, we reveal a surprising disconnect between pulmonary eosinophilia and cryptococcal burden and dissemination. This research has 2 important implications. Firstly, a lack of CD200R1 signalling enhances immune responses regardless of cytokine polarisation, and secondly reducing eosinophils does not allow protective immunity to develop in susceptible fungal system. Therefore, agonists of CD200R1 may be beneficial for eosinophilic pathologies.

Keywords: CD200R1 · Cryptococcus neoformans · eosinophilia · lung · Th2 immunity

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Introduction

The pleiotropic functions of myeloid cells require tight regulation to promote immunity to potentially harmful pathogens whilst limiting immunopathology. This regulation is achieved by both soluble factors and cell contact-dependent interactions, for example those mediated through CD200 receptor (CD200R1). CD200R1 is a type 1 transmembrane protein and member of the immunoglobulin superfamily that is predominantly expressed by cells of the myeloid lineage. Ligation with the more broadly distributed ligand, CD200, delivers a unidirectional inhibitory signal to the myeloid cell [1]. Mice lacking CD200 display elevated numbers of activated macrophages and develop more aggressive autoimmune diseases [2, 3], suggesting that CD200 restrains the tonic activation of macrophages to promote homeostasis. Immunotherapeutic administration of CD200 alleviates excessive inflammation seen in auto- and alloimmune conditions [4–6].

Alveolar macrophages are the sentinels of the airways and determine the magnitude and orientation of the immune response [7]. We have previously reported that these cells express high basal
levels of CD200R1 that interacts with CD200 expressed on the luminal aspect of the airway epithelium [7]. Alveolar macrophages are de-regulated in naïve mice lacking CD200 [8]. Furthermore, during influenza viral infection, mice lacking CD200 clear virus more efficiently, but develop pronounced immunopathology that is slower to resolve. Restoration of CD200 signalling returns inflammatory cell control. The CD200−CD200R1 axis therefore balances pathogen clearance and inflammation [9, 10].

CD200R1 has predominantly been studied in the context of Th1-driven inflammatory diseases/infections [9, 11–13]. In fungal infection, Th2 responses are generally deleterious, but the influence of CD200R1 is not known. Cryptococcus neoformans is an encapsulated budding yeast causing disease in immunocompetent individuals, but immunologically compromised are at greatest risk [14–16]. Failure to control fungal burden results in the lung results in dissemination to extra-pulmonary tissues, including the brain (cryptococcosis). In recent years clinical cases of cryptococcosis have escalated and in the AIDS infected population 6–8% develop cryptococcus-associated meningitis [17, 18].

Whilst a strong Th1 response is critical in resistance to C. neoformans, a Th2-driven eosinophilia is observed in the bronchoalveolar lavage (BAL) fluid of some patients, and hypereosinophilia reported with disseminated cryptococcal disease [19]. Similarly, in mouse models of C. neoformans infection, resistant mice (CBA, C.B-17, BALB/c) generally produce higher concentrations of type 1 cytokines [20–22]. In contrast, susceptible strains (C57BL/6, C3H and B10.D2) develop a Th2 driven pulmonary eosinophilia where up to 40% of airway cells are eosinophils [23, 24]. This response is non-protective and results in tissue damage resulting from degranulation and crystal deposition by eosinophils [20].

The role of CD200R1 signalling in fungal infection and, more broadly, Th2-focused inflammation is yet to be determined. As blockade of CD200R1 enhances type I cytokine responses, we postulated that the response to fungal disease would switch from non-protective to protective. Surprisingly, a loss of CD200R1 actually enhanced Th2 responses and pulmonary eosinophilia, but had no effect on fungal burden or dissemination. Conversely, agonists to CD200R1 reduced pulmonary eosinophilia without impacting on fungal clearance. CD200R1 therefore alters the magnitude, but not phenotype of fungal lung disease. These studies also highlight a clear disconnect between C. neoformans clearance and pulmonary eosinophilia. Thus, protection from fungal lung disease may not occur by eliminating Th2-associated eosinophils, but rather specific induction of a Th1 program of inflammation.

Results

Alveolar macrophages are the predominant CD200R1 expressing cells during C. neoformans infection

The C. neoformans susceptible C57BL/6 mouse model was utilized to dissect the role of CD200R1 in modulating Th2 inflammation and fungal clearance. C. neoformans infection induced cellular infiltration into the airways and lung parenchyma, which peaked at 14 days, but persisted 35 days after infection. Eosinophils were the predominant cell type in the airways and lung tissue (Fig. 1A). As previously described, this Th2-driven inflammation does not fully resolve fungal infection, with persistence in the airways and lung at 35 days post infection and dissemination to the brain (Fig. 1B).

As previously reported [8], a high level of CD200R1 expression was detected on alveolar CD11c+ macrophages in the airways and lungs of naïve mice, with expression remaining high upon C. neoformans infection (Fig. 1C and 1D). Eosinophils, neutrophils and CD4+ T cells were devoid of CD200R1 at homeostasis and upon C. neoformans infection (Fig. 1C), suggesting that any impact of CD200R1 manipulation in the context of fungal infection was likely mediated through macrophages (refer to Supplementary Fig. 1 for flow cytometry gating strategy).

CD200R1 limits eosinophilic inflammation

We anticipated that removal of CD200R1 would enhance immunity and C. neoformans clearance. As expected, the cellularity of the airspaces increased in C. neoformans infected mice. An absence of CD200R only caused a mild increase in cellularity at day 14 after infection. (Fig. 2A). Total cell numbers and total numbers of alveolar macrophages in the lung parenchyma were comparable between CD200R1−/− and littermate controls (Fig. 2B and 2C). Despite the similarity in total lung cellularity, total numbers of alveolar CD11c+ macrophages in the airways were raised in CD200R1−/− mice during C. neoformans infection (Fig. 2D), as we have previously reported on Th-1 and Th-17 skewed pulmonary infection models11. Together, this data re-enforces our assertion that the primary alteration may lie in the CD200Rhi macrophage compartment. The dominant effect in CD200R1−/− mice during C. neoformans infection however, was the striking increase of airway and lung parenchyma eosinophils (Fig. 2E). This could not be explained by an increase in fungal burden since CFUs in the airways (Fig. 2F) and lung tissue (Fig. 2G) were comparable between wild-type and CD200R1−/− mice. Fungal dissemination to the brain and spleen (Fig. 2H and 2I) was also unaffected. Thus an absence of CD200R1 signalling seemingly augmented eosinophilic pathology in C57BL/6 mice, without a significant improvement in fungal clearance.

Elevated type 2 cytokines in C. neoformans infected CD200R−/− mice

To determine why eosinophils were raised in CD200R1 knockout mice during C. neoformans infection, eotaxin-2, a potent eosinophil chemoattractant, primarily derived from alveolar macrophages, was measured. Eotaxin-2 protein (Fig. 3A) and mRNA in sorted alveolar macrophages (Fig. 3B), was elevated in C. neoformans infected CD200R1−/− mice. Neutralization of eotaxin-2 in wild-type mice reduced airway (Supplementary Fig. 2A and B) and lung (Supplementary Fig. 2C and D) eosinophils, highlighting...
Figure 1. Alveolar macrophages are the predominant cell type expressing CD200R during *C. neoformans* infection. Wild-type mice were infected intranasally with *C. neoformans* (strain 52D). Total numbers and proportions of eosinophils in the airways and lung (A) were determined by flow cytometry. Total fungal CFU in the airways, lung tissue, brain and spleen (B) were determined by plating out on selective agar. CD200R1 expression on cells isolated from airways and the lung tissue (C and D) of wild-type mice were analysed by flow cytomtery at day 0 and 14 post infection with *C. neoformans*. Histogram overlay depicting the levels of CD200R1 expression on alveolar CD11c⁺ macrophages, eosinophils (CD11c⁻CD11b⁺SiglecF⁺), neutrophils (CD11c⁻CD11b⁺Ly6G⁺) and CD4⁺ T cells. ND, not detected, gray: isotype control, black: CD200R1 expression. (D) CD200R expression levels (by relative geometric mean of the stain and its respective isotype control) on alveolar CD11c⁺ macrophages were measured in the airways and the lung tissue of naïve mice (n = 3) and mice infected with *C. neoformans* (n = 5). Open circle, naive; Closed triangle, infected. Data shown represent 3–5 mice per group from one experiment and are representative of three independent experiments. Data shown as mean ± SEM. Statistical significance was determined by Mann–Whitney U-test, *p < 0.05; **p < 0.01; ***p < 0.001.

the importance of this chemokine in driving eosinophilia in this model. Similarly, eotaxin-2 neutralization had no impact on fungal burden in the airways or the lung of treated mice (Supplementary Fig. 2E and F), reinforcing the concept that there is a disconnect between eosinophilia and fungal control. Similarly, the eosinophil survival factor IL-5 (Fig. 3C), and other classical type 2 cytokines IL-13 (Fig. 3D) and IL-4 (Fig. 3E) were raised in the airways and lung homogenate of CD200R1⁻/⁻ animals.

Whilst macrophages are the likely source of elevated eotaxin-2 [26, 27], the other elevated cytokines may derive from another cellular source [28–30]. We observed no differences in total numbers of CD4⁺ T cells between *C. neoformans* infected CD200R1⁻/⁻ and wild-type mice (Fig. 4A). However, intracellular cytokine staining revealed that the CD4⁺ T cells present produced more IL-13 (Fig. 4B and 4D) and IL-5 (Fig. 4C and 4E) in CD200R1⁻/⁻ mice.
C. neoformans infected CD200−/− mice also exhibit enhanced eosinophilic inflammation

The interaction of CD200R1 with CD200 produces a unidirectional inhibitory signal to the CD200R1 bearing cell. We therefore reasoned that an absence of CD200 should result in a similar outcome as CD200R1−/− mice during lung fungal infection. However, it is now acknowledged that there are four murine CD200R isoforms (R1-R4), the precise functions of which are still poorly defined. Furthermore, uncertainty persists as to whether CD200 is the natural ligand for all receptors [3, 21, 22]. To validate our observations seen in CD200R1−/− mice and identify any potential ligand redundancy, mice deficient in CD200 were also analysed for their response to C. neoformans. Indeed, mice lacking CD200 displayed greater airway (Fig. 5A) and lung (Fig. 5B) eosinophils relative to wild-type controls, although the phenotype was far more dominant in the lung tissue. Once again, there was no significant reduction in fungal clearance in the airways, lung tissue (Fig. 5C) or brain (Fig. 5D) of CD200−/− mice, although the CFUs were trending down within the airways.

Targeting the CD200-CD200R axis during C. neoformans infection modulates eosinophilic inflammation

To exclude additional, inherited defects in CD200/R1−/− and CD200−/− animals at steady state, we administered a CD200 antagonistic antibody (OX90) to C. neoformans infected wild-type mice and once again observed increased lung eosinophils in treated animals (Fig. 6A). Furthermore and in keeping with our previous findings, no differences were observed in fungal clearance from the airways and lung tissue (Fig. 6B).

If an antagonist increases eosinophils, then an agonistic antibody to CD200R1 (OX110) should ameliorate inflammation and associated pathology. OX110 administration to C. neoformans
Figure 3. CD200R1−/− mice exhibit augmented type 2 cytokines following C. neoformans infection. Wild-type and CD200R1−/− mice were infected intranasally with C. neoformans, and levels of eotaxin-2 (A), IL-5 (C), IL-13 (D), IL-4 (E) in the airways and lung homogenate were assessed by ELISA at indicated times post infection. Alveolar macrophages were isolated from the lung following 14 days post infection by fluorescence-activated cell sorting and the fold changes in eotaxin-2 mRNA levels (B) were assessed by Q-PCR. Data show results for five mice per group from one experiment and are representative of two independent experiments. Solid Line, wild-type; dashed line, CD200R1−/− mice. Data shown as mean ±SD and statistical significance was determined by student’s unpaired t-test. *p<0.05; **p<0.01; ***p<0.001.

Discussion

The discovery of CD4+ T cell subsets with polarised expression of specific cytokines has transformed our understanding of what constitutes a protective response and explains the diverse outcome on infection with the same pathogen in mice of different haplotype. Th-2 type cytokine responses to the majority of viral, bacterial and fungal pathogens constitute a non-protective response. Most in vivo models of inflammation show that BALB/c (H-2d) mice respond with a more Th2-cytokine response whereas C57BL/6 (H-2b) mice are more prone to Th1-cytokines. The murine models of C. neoformans infection, however, causes “non-protective”, Th2-driven eosinophilic lung pathology (the extent of which depends on T1/ST2 expression [23]) and fungal meningitis in C57BL/6 mice, whereas BALB/c mice are non-eosinophilic and relatively protected. By manipulating CD200R1 activity, we show that it infected mice reduced eosinophilic inflammation in the airways, but not the lungs (Fig. 6C) at day 14 post infection. Again, manipulation of the CD200R1 pathway had no significant impact on fungal clearance from the airways or lung tissue (Fig. 6D).

© 2019 The Authors. *European Journal of Immunology* published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
critically regulates the amplitude of eosinophilia and type 2 cytokines, but has no significant impact on cryptococcal burden or dissemination. Eosinophils have previously been reported to phagocyte opsonised *C. neoformans* and wall off the fungus in peri-vascular eosinophilic cuffs lining the alveolar space [24]. Despite enhanced eosinophilia in CD200R−/− mice, fungal burden was not significantly altered, which is in contrast to other studies where a reduction in eosinophilia (for example in surfactant protein D, Scavenger Receptor A, NADPH oxidase or eosinophil knockout mice) [25, 26] is associated with reduced fungal burden.

This outcome is evident in human disease where susceptibility to HIV-associated cryptococcal meningitis is not associated with the induction of an incorrect inflammatory response. For example, stimulation of peripheral blood CD4+ T cells from such patients with a fungal protein does not induce Th2-associated cytokines, nor are they abundant in soluble form in the cerebrospinal fluid [27–29]. Rather, susceptibility stems from a lack of type-1-associated cytokines (IFN, TNF, IL-6 and MCP-1), an observation supported by cryptococcal susceptibility studies in murine models [30–32]. Not only are type 1 cytokine responses crucial for cryptococcal clearance, but they need to be present early. Decreased cryptococcal-specific IFN-γ responses [27, 33, 34] are associated with the condition HIV-associated cryptococcal immune reconstitution inflammatory syndrome (CM-IRIS) (for a review see [35, 36]). The ingredients for this condition include HIV-mediated suppression of immunity, cryptococcal infection (either sub-clinical or clinical) and rapid recovery of immunity after commencement of anti-retroviral therapy leading to inflammatory disease. However, if cryptococcal-specific IFN-γ is sufficient at the outset then the fungal load is more likely to be low enough to prevent inflammation upon immune restitution. The results presented here, and the clinical observations in HIV patients with cryptococcal meningitis imply that induction of type 1 cytokines irrespective of type 2 cytokine neutralisation may prove more beneficial. Modulating immune responses to a pro-inflammatory profile has continually proven protective in the case of cryptococcal lung disease. For example, ligation of the late T cell co-stimulator OX40 (CD134) [37], blockade of IL-10 receptor [38] administration of type 1 IFNs [39] TLR9 agonism [40] infection with
Figure 5. *C. neoformans* infected CD200<sup>−/−</sup> mice also exhibit an augmented eosinophilic inflammation. Wild-type and CD200<sup>−/−</sup> mice were infected i.n with *C. neoformans*. Total numbers of eosinophils in the airways (A) and lung tissue (B) of wild-type and CD200<sup>−/−</sup> infected mice were determined by flow cytometry. Open box, wild-type; filled box, CD200<sup>−/−</sup>. Data presented as box and whisker plots with median. Total CFUs were determined by plating out BALF and lung (C) and brain (D) from wild-type and CD200<sup>−/−</sup> mice. Open circle, wild-type; closed triangle, CD200<sup>−/−</sup>. Data shown represents 5 mice per group from one experiment and is representative of two independent experiments. Statistical significance was determined by Mann–Whitney U-test, *p* < 0.05; **p** < 0.01.

interferon-gamma producing *C. neoformans* [41] enhance Th1- and/or Th17-associated cytokines and improve *C. neoformans* clearance.

Though the amplitude of eosinophilia does not significantly impact on *C. neoformans* burden in our studies, the mechanism of increased amplitude may be relevant to other non-infectious allergic lung diseases including asthma. The expression of CD200R1 was not detected on the surface of eosinophils implying that the increase in the numbers of this cell type is not a direct consequence of the removal of the inhibitory signal imparted by CD200. Instead, the raised eosinophilia we observed in the absence of CD200R1 likely arises from the enhanced levels of eosinophilic chemoattractant cytokines IL-5 and eotaxin-2. We therefore propose that enhanced eosinophilia is due primarily to increased eotaxin-2 production from CD200R1<sup>+</sup> airway macrophages and show by its neutralisation that eotaxin-2 plays a non-redundant role in eosinophilic inflammation in this model. Whilst macrophages are the likely source of the elevated eotaxin-2, they are unlikely to represent a prominent source of IL-13, IL-5 and IL-4 during *C. neoformans* infection, with previous studies highlighting the critical role of ILC2 and Th2 cells as source of these cytokines [42–44]. Accordingly, we observed an increase in Th2 cytokine producing CD4<sup>+</sup> T cells in *C. neoformans* infected CD200R1 knockout mice. It is feasible that the altered macrophage compartment in these knockout animals further promotes a Th2 response by releasing CCL17 and CCL22 chemokines known to recruit Th2 cells to the site of
infection. Furthermore, we have previously demonstrated that an augmented T cell response to influenza infection was observed in CD200−/− animals secondary to augmented macrophage / DC responses, potentially attributable to enhanced antigen presentation [8]. This may also be true in the context of cryptococcal infection, but in an environment that would promote a Th2 skewed T cell response.

In conclusion, our study has identified a novel role for CD200R1 in eosinophil regulation and proposes that this potent inhibitory receptor can be targeted in vivo to regulate eosinophil-dependent pathologies.

**Materials and methods**

**Mice and pathogens**

All animal procedures and care conformed strictly to the United Kingdom Home Office Guidelines under the Animals (Scientific Procedures) Act 1986 and the protocols were approved by the Home Office of Great Britain. Eight- to 12-wk-old female C57BL/6 (Harlan Olac, Bicester, UK), CD200−/− and CD200−/− were kept in pathogen-free conditions at Bio Safety level 2. *C. neoformans* strain 52D was obtained from the American Type Culture Collection (ATCC 24067) and maintained on Sabouraud dextrose agar (Beckton Dickson). For infection, a single colony of *C. neoformans* was resuspended in Sabouraud dextrose broth (1% neopeptone and 2% dextrose; Becton Dickson) and grown to stationary phase (48–72 h) in a rotating culture at room temperature. The cultures were washed in phosphate-buffered saline (PBS), counted on a hemocytometer, and adjusted in sterile PBS to the desired infective concentration.

**Mouse infection and treatment**

Mice were anesthetized using isoflurane and infected intranasally (i.n.) with 2 × 10⁴ CFU (Colony-forming units) of *C. neoformans* in 50 µL of sterile PBS. In some experiments wild-type C57BL/6 mice were injected intraperitoneally (i.p) with 100 µg OX110 (rat IgG1 agonistic anti-mouse CD200R), 100 µg of OX90 (rat IgG1 antagonistic anti-mouse CD200), 500 µg Eotaxin-2 monoclonal antibody (Rat IgG2a Clone 106521, Research and Diagnostic Systems) or 100 µg control rat IgG (Serotec, UK) 1 day before and every other day following infection. Mice were sacrificed on indicated days by injection of 3 mg of pentobarbitone.

**Enumeration of Cryptococcus neoformans**

Lungs and brain were homogenized by passage through 100-µm cell strainers (BD Labware). A total of 100 µL of cell suspension from lung homogenate, brain homogenate, and BAL fluid were diluted in PBS and incubated at room temperature for 48 h on
Sambouraud dextrose agar plates. The total CFU per sample was then determined (number of colonies x dilution factor x original cell suspension volume).

Cell recovery and isolation

Bronchoalveolar lavage (BAL) cells were collected by inflating the lung 3 times with 1.5 ml of PBS via an intratracheal cannula and centrifuged for 5 min at 240 g x g. The supernatant was stored at -80°C for cytokine quantification and the cell pellets were resuspended in 500 µl R10F (RPMI-1640 supplemented with 10% foetal calf serum and 1% penicillin/streptomycin) for flow cytometry. Lung lobes were removed, shredded using scissors and digested at 37°C with agitation in the presence of 0.13 mg/ml Liberase III enzyme (Roche) and 50 µg DNAse I (Roche) for 30 min and the reaction stopped with 2mM EDTA. Digested lung tissue was disrupted into single cell suspensions by passage through a 100-µM cell strainers and cell suspensions were centrifuged for 5 min at 240 x g. Red blood cells were lysed by resuspension of the pellets in ACK buffer (0.15 M ammonium chloride, 1 M potassium hydrogen carbonate and 0.01 mM EDTA, pH 7.2) for 3 min at room temperature. Cells were spun, washed and resuspended with R10F media. Cell viability was assessed by haemocytometer and trypan blue exclusion.

Flow cytometry

Cells were stained for surface markers and analyzed by flow cytometry (Supplementary Fig. 1). All antibodies were purchased from BD Pharmingen (Oxford, UK), R&D systems (Abingdon, UK) or eBioscience, UK. In brief, for lymphocyte identification 1 x 10^6 cells were stained using αCD3-PerCP (Clone 17A2), αCD4-PerCP-Cy5.5 (Clone RM4-5). Alveolar macrophages (CD11c+ cells) in the lung and airways were identified using αCD11b-PerCP-Cy5.5 (Clone RM4-5). Eosinophils (CD11b+CD11c+SiglecF+) and neutrophils (CD11b+CD11c-Ly6G+) were identified using αCD11b-PerCP-Cy5.5 (Clone M1/70) and αCD11c-APC-Cy7 (Clone N418). For eosinophils (CD11b+CD11c-SiglecF+) and neutrophil identification (CD11b+CD11c-Ly6G+) αSiglecF-PE (Clone E50-2440) and αLy6G-FITC (Clone 1A8) was used respectively. Expression of CD200R1 on different cell populations were identified using αCD200R-APC (Clone OX110). All antibodies were diluted in phosphate-buffered saline (PBS) containing 1% bovine serum albumin (BSA)/0.05% sodium azide (PBA). Cells were stained for 30 min on ice, washed with PBA, and spun for 5 min at 240 x g. After washing, cells were then fixed for 20 min at room temperature with 2% formaldehyde/PBS. Cells were then washed in PBA and data were acquired on BD FACS Canto II.

Cytokine quantification

Concentrations of cytokines Eotaxin-2, and IL-5, IL-13 and IL-4 (eBioscience) in bronchoalveolar lavage (BAL) fluid and lung homogenates were measured using Duoset ELISA kits according to the manufacturer’s instructions.

Real-time quantitative PCR

Purified alveolar macrophages were lysed using RLT buffer (Qiagen, UK) and RNA extracted by Qiagen RNeasy mini kit (Qiagen, UK) as per manufacturer’s instructions. cDNA was generated using the Applied Biosystems high-capacity RNA-to-cDNA kit (Life Technologies, UK). RNA expression levels of Eotaxin-2 (Mm00444701_m1, Applied biosystems) were normalised to GAPDH (Mm99999915_g1). The 2^-ΔΔCT relative quantification method was used to determine the relative expression level of Eotaxin-2 compared to control group.

Statistics

All statistical analysis was performed with Prism version 5 software (GraphPad Software). Mann-Whitney statistical test was used for comparison with wild-type controls. Data presented as box and whisker plots, with the box showing the median and the 25th and 75th percentiles. Whiskers of the graph show the largest and the smallest values. *p values < 0.05, **p<0.01, ***p<0.001.

Acknowledgements: R.J.S. is a Wellcome Trust Senior Research Fellow (209458/Z/17/Z). T.H. is funded by a Wellcome Trust investigator award (202865/Z/16/Z).

Conflict of interest: The authors declare no financial or commercial conflict of interest.

References

1 Barclay, A. N., Wright, G. J., Brooke, G. and Brown, M. H., CD200 and membrane protein interactions in the control of myeloid cells. Trends Immunol. 2002. 23: 285–290.
Huffnagle, G. B., Boyd, M. B., Street, N. E. and Lipscomb, M. F., IL-5 is required for eosinophil recruitment, crystal deposition, and mononuclear cell recruitment during a pulmonary Cryptococcus neoformans infection in genetically susceptible mice (C57BL/6). *J. Immunol.* 1998. 160: 2393–2400.

21 Wright, G. J., Cherwinski, H., Foster-Cuevas, M., Brooke, G., Puklavec, M. J., Bigler, M., Song, Y. et al., Characterization of the CD200 receptor family in mice and humans and their interactions with CD200. *J. Immunol.* 2003. 171: 3034–3046.

22 Hatherley, D., Cherwinski, H. M., Shooshfek and Barclay, A. N., Recombinant CD200 protein does not bind activating proteins closely related to CD200 receptor. *J. Immunol.* 2005. 175: 2469–2474.

23 Peihler, D., Grahnhart, A., Eschke, M., Richter, T., Köhler, G., Stenzel, W. and Alber, G., T1/ST2 promotes T helper 2 cell activation and polyfunctionality in bronchopulmonary mycosis. *Mucosal Immunol.* 2013. 6: 405–414.

24 Feldmesser, M., Cassadesvall, A., Kress, Y., Spira, G. and Olfaosky, A., Eosinophil-Cryptococcus neoformans interactions in vivo and in vitro. *Infect. Immun.* 1997. 65: 1899–1907.

25 Qiu, Y., Dayritt, J. K., Davis, M. J., Carolan, J. F., Osterholzer, J. J., Curtis, J. L. and Olszewski, M. A., Scavenger receptor A modulates the immune response to pulmonary Cryptococcus neoformans infection. *J. Immunol.* 2013. 191: 238–248.

26 Peihler, D., Stenzel, W., Grahnert, A., Held, J., Richter, L., Köhler, G., Richter, T. et al., Eosinophils contribute to IL-4 production and shape the T helper cytokine profile and inflammatory response in pulmonary cryptococcosis. *Am. J. Pathol.* 2011. 179: 733–744.

27 Jarvis, J. N., Casazza, J. P., Stone, H. H., Meintjes, G., Lawn, S. D., Levitz, S. M., Harrison, T. S. et al., The phenotype of the Cryptococcus-specific CD4+ memory T-cell response is associated with disease severity and outcome in HIV-associated cryptococcal meningitis. *J. Infect.* 2013. 207: 1817–1828.

28 Siddiqui, A. A., Brouwer, A. E., Wuthiekanun, V., Jaffar, S., Shattuck, R., Irving, D., Sheldon, J. et al., IFN-gamma at the site of infection determines rate of clearance of infection in cryptococcal meningitis. *J. Infect.* 2005. 47: 1746–1750.

29 Jarvis, J. N., Meintjes, G., Bicanic, T., Buffa, V., Hogan, L., Mo, S., Tomlinson, G. et al., Cerebrospinal fluid cytokine profiles predict risk of early mortality and immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis. *Ala. Path.* 2012. 7:e47740.

30 Wormley, F. L., Perfect, J. R., Steele, C. and Cox, G. M., Protection against cryptococcosis by using a murine gamma interferon-producing Cryptococcus neoformans strain. *Infect. Immun.* 2007. 75: 1453–1462.

31 Uicker, W. C., Doyle, H. A., McCracken, J. P., Langlois, M. and Buchanan, K. L., Cytokine and chemokine expression in the central nervous system associated with protective cell-mediated immunity against Cryptococcus neoformans. *Med. Mycol.* 2005. 43: 27–38.

32 Zhou, Q., Gault, R. A., Kozel, T. R. and Murphy, W. J., Protection from direct cerebral cryptococcosis infection by interferon-gamma-dependent activation of microglial cells. *J. Immunol.* 2007. 178: 5753–5761.

33 Chang, C. C., Omarjee, S., Lim, A., Spelman, T., Gosnell, B. L., Carr, W. H., Elliott, J. H. et al., Chemokine levels and chemokine receptor expression in the blood and the cerebrospinal fluid of HIV-infected patients with cryptococcal meningitis and cryptococcosis-associated immune reconstitution inflammatory syndrome. *J. Infect.* 2013. 208: 1604–1612.

34 Bouwla, D. R., Bonham, S. C., Meya, D. B., Wiesner, D. L., Park, G. S., Kambugu, A., Janoff, E. N. et al., Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with
subsequent immune reconstitution inflammatory syndrome. *J. Infect. Dis.* 2010. 202: 962–970.

35 Longley, N., Harrison, T. S. and Jarvis, J. N., Cryptococcal immune reconstitution inflammatory syndrome. *Curr. Opin. Infect. Dis.* 2013. 26: 26–34.

36 Meya, D. B., Manabe, Y. C., Soulware, D. R. and Janoff, E. N., The immunopathogenesis of cryptococcal immune reconstitution inflammatory syndrome: understanding a conundrum. *Curr. Opin. Infect. Dis.* 2016. 29: 10–22.

37 Humphreys, I. R., Walzl, G., Edwards, L., Rae, A., Hill, S. and Hussell, T., A critical role for OX40 in T cell-mediated immunopathology during lung viral infection. *J. Exp. Med.* 2003. 198: 1237–1242.

38 Murdock, B. J., Teitz-Tennenbaum, S., Chen, G.-H., Dila, A. J., Malachowski, A. N., Curtis, J. L., Olszewski, M. A. et al., Early or late IL-10 blockade enhances Th1 and Th17 effector responses and promotes fungal clearance in mice with cryptococcal lung infection. *J. Immunol.* 2014. 193: 4107–4116.

39 Leopold Wager, C. M., Hole, C. R., Wozniak, K. L., Olszewski, M. A., Mueller, M. and Wormley, F. L., STAT1 signaling within macrophages is required for antifungal activity against Cryptococcus neoformans. *Depe GS* Jr., ed. *Infect. Immun.* 2015. 83: 4513–4527.

40 Qiu, Y., Zeltzer, S., Zhang, Y., Wang, F., Chen, G.-H., Dayrit, J., Murdock, B. J. et al., Early induction of CCL7 downstream of TLR9 signaling promotes the development of robust immunity to cryptococcal infection. *J. Immunol.* 2012. 188: 3940–3948.

41 Christianson, C. A., Goplen, N. P., Zafar, I., Irvin, C., Good, J. T., Rollins, D. R., Gorentla, B. et al., Persistence of asthma requires multiple feedback circuits involving type 2 innate lymphoid cells and IL-33. *J. Allergy Clin. Immunol.* 2015. 136: 59–68.e14.

Abbreviation: CD200R1: CD200 receptor

Full correspondence: Tracy Hussell, Manchester Collaborative Centre for Inflammation Research (MCCIR), Manchester, UK

Email: tracy.hussell@manchester.ac.uk

The peer review history for this article is available at https://publons.com/publon/10.1002/eji.201847861

Received: 10/8/2018

Revised: 17/4/2019

Accepted article online: 31/5/2019